Clinical Trial of New Elastomer for Maxillofacial Prosthetics

University of Louisville (UOFL)

Status and phase

Completed

Phase 3

Conditions

Facial Neoplasms

Head Injuries, Penetrating

Head and Neck Neoplasms

Birth Injuries

Treatments

Combination Product: Chlorinated polyethylene elastomer

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00123097

5U01DE014543 (U.S. NIH Grant/Contract)

U01DE014543 (U.S. NIH Grant/Contract)

NIDCR-14543

Details and patient eligibility

About

The purpose of this study is to evaluate a new rubber material used to make prosthetic replacements of the face lost to cancer, trauma, or birth defects.

Full description

Maxillofacial prosthetics is a subspecialty of prosthodontics, providing the clinical rehabilitation treatment of patients who have lost parts of the face due to cancer, trauma, or birth defects. It is an orphan field that:

treats few patients, making the subspecialty unprofitable for manufacturers to develop new materials;
offers fundamental rehabilitation and improvement in the quality of life to patients who may have exhausted personal or third party funding; and
provides a dental solution to an essentially medical problem.

Silicone rubber materials have been used for facial rehabilitation for more than 4 decades with few improvements. There is a clear need for new, alternative, and more economic materials for extraoral maxillofacial prostheses. Research at Gulf South Research Institute in New Orleans by the Principal Investigator and others in the 1970s and 1980s developed an alternative low-cost thermoplastic industrial rubber material (chlorinated polyethylene, CPE) that met all toxicological (safety) and physical (effectiveness) requirements. A Phase 2 clinical trial at the time yielded equivocal results when compared to conventional but costly silicone rubber products.

This research is a controlled, randomized, single-crossover, double-blinded investigator-initiated multicenter Phase 3 clinical trial treating 100 patients that evaluates:

experimental thermoplastic CPE; and
control silicone (Silastic Adhesive A/MDX4-4210) materials for non-inferiority of CPE based on functional and subjective characteristics, and on the quality of life.

The clinical centers of the trial are at M.D. Anderson Cancer Center in Houston, Texas, and at the Toronto Sunnybrook Regional Cancer Centre in Toronto, Canada.

Enrollment

42 patients

Sex

All

Ages

21+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Requires treatment for developmental or acquired extraoral facial defect
Fully healed wound (6 months after surgery and/or radiation)
Defect no larger than 9 x 12 cm (3.5 x 4.5 inches, the diameter of a giant bronze flask)
Cognizant enough to answer questionnaires
Agrees to wear the prosthesis at least 6 hours per day
Agrees to use the prescribed adhesive (Epithane-3 - now called Daro Adhesive Extra Strength) and clean and store as instructed
Plans to be able to return to the research institution for a 10 month period
Able to manage prosthesis him/herself or with caregiver for a 10 month period
Karnofsky score greater than or equal to 60 (www.hospicepatients.org/karnofsky.html)
No framework or implant/magnet retention
No multiple recurrences of tumor
No hypersensitivity to adhesives or test materials
No current systemic or topical facial steroid treatment
Not legally blind
Not expected to have further surgeries to defect, radiation therapy, or other cytoreductive therapy over the next 10 months
No evidence of active skin condition/disease
Not an infectious risk patient